Merck & Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results; Highlights Significant Regulatory Approvals and Clinical Milestones
Merck's Playing with Heart Program Teams Up With Professional Baseball Clubs and Baseball Legends to Help Raise Awareness About LDL-C, Called "Bad" Cholesterol, and How It May Impact the Risk of Heart Attack or Stroke
Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.
Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma
FDA Grants Priority Review for KEYTRUDA® and KEYTRUDA QLEX , Each with Padcev® , for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer
European Commission Approves Merck's ENFLONSIA for the Prevention of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants During Their First RSV Season
Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy
Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 , an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration
European Commission Approves KEYTRUDA® Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens
